
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is poised for a positive financial trajectory, with a projected modified CY25 pre-tax adjusted operating income of $4,175 million, marking a year-over-year increase of 7.0%. The company's Evernorth segment is also expected to show solid growth, with an estimated 5.8% year-over-year increase in earnings, driven by robust specialty volume growth, including the adoption of biosimilars and expansion in clinical care services. Additionally, significant improvements in the Stop-Loss Medical Loss Ratio (MLR) are forecasted, with an anticipated decline from 91.0% in CY26 to a new target of 89.0% in CY27, reflecting Cigna's ongoing strategic investments and operational efficiencies.
Bears say
The Cigna Group experienced a significant earnings miss in the fourth quarter of 2024, with adjusted EPS reported at $6.64, representing a 15% shortfall against consensus estimates and reflecting a 2.2% year-over-year decline. The company faced unfavorable medical membership trends, reporting a total enrollment of 19.147 million, which marks a 3.2% year-over-year decrease, primarily driven by challenges in the Individual and Family Plans category due to pricing actions in select markets. Additionally, the elevated incidence of high-cost claimants in the Stop-Loss segment exacerbated the challenges faced by Cigna, contributing to overall pressure on its financial performance and outlook.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares